View

References

  • 1. Greenberg PL, Attar E, Bennett JM, et al. NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. J Natl Compr Canc Netw. 2011;9(1):30–56.
  • 2. Breccia M, Federico V, Loglisci G, et al. MDS-Specific Comorbidity Index (MDS-CI) identifies overall survival differences in myelodysplastic syndrome patients. Blood. 2011;118 (21):3793.
  • 3.Kubasch AS, Platzbecker U. Patient stratification in myelodysplastic syndromes: How a puzzle may become a map. Hematology Am Soc Hematol Educ Program. 2020;2020(1):418–425.
  • 4. Carraway HE, Saygin C. Therapy for lower-risk MDS. Hematology Am Soc Hematol Educ Program. 2020;2020(1):426– 433.
  • 5. Scott BL. Existing agents, novel agents, or transplantation for high-risk MDS. Hematology Am Soc Hematol Educ Program. 2020;2020(1):411–417.
  • 6.Zeidan AM, Linhares Y, Gore SD. Current therapy of myelodysplastic syndromes. Blood Rev. 2013;27(5):243–259.
  • 7. Giri AK, Aittokallio T. DNMT inhibitors increase methylation in the cancer genome. Front Pharmacol. 2019;10:385.
  • 8. Zeidan AM, Gore SD, McNally DL, et al. Lenalidomide performance in the real world: Patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes. Cancer. 2013;119(21):3870–3878.
  • 9. Steensma DP. Clinical consequences of clonal hematopoiesis of indeterminate potential. Blood Adv. 2018;2(22):3404– 3410.
  • 10. Chung SS, Park CY. Aging, hematopoiesis, and the myelodysplastic syndromes. Blood Adv. 2017;1(26):2572–2578.
  • 11. Sekeres MA, Watts JM, Radinoff A, et al. Efficacy and Safety of Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS) from Study P-2001. Available at: https://ash.confex.com/ash/2020/webprogram/Paper135840.html. Accessed on: 04 January 2021.
  • 12. Garcia JS, Wei AH, Borate U. Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study. Blood. 2020;136 (Suppl 1):55–57.
  • 13. Cadenas FL, Lumbreras E, Xicoy B, et al. Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients—Interim Analysis of the European Sintra-REV Trial. Blood. 2020;136(Suppl 1):28–29.
  • 14. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplanteligible newly diagnosed multiple myeloma: The GRIFFIN trial. Blood. 2020;136(8):936–945.
  • 15. Kumar S. Emerging options in multiple myeloma: Targeted, immune, and epigenetic therapies. Hematology Am Soc Hematol Educ Program. 2017;2017(1):518–524.
  • 16. Lipe B, Vukas R, Mikhael J. The role of maintenance therapy in multiple myeloma. Blood Cancer J. 2016;6(10):e485.
  • 17. van de Donk NWCJ. Sequencing multiple myeloma therapies with and after antibody therapies. Hematology Am Soc Hematol Educ Program. 2020;2020(1):248–258.
  • 18. Soleymanian T, Soleimani A, Musavi A, et al. Outcome of patients with multiple myeloma and renal failure on novel regimens. Saudi J Kidney Dis Transpl. 2016;27(2):335–340
  • 19. Chu P. Managing multiple myeloma patients with renal failure. Hong Kong J of Nephr. 2013;15:62–67.
  • 20. Dimopoulos MA, San-Miguel J, Belch A, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of POLLUX. Haematologica. 2018;103(12):2088–2096.
  • 21. Weisel KC, Dimopoulos MA, Moreau P, et al. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma. Haematologica. 2016;101(7):872–878.
  • 22. Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv. 2017;1(7):449–454.
  • 23. Wudhikarn K, Wills B, Lesokhin AM. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action. Best Pract Res Clin Haematol. 2020;33(1):101143.
  • 24. Kaufman JL, Laubach JP, Sborov D, et al. Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. Blood. 2020;136 (Suppl 1):45–46.
  • 25. Facon T, Venner CP, Bahlis N, et al. The Phase 3 TOURMALINE-MM2 Trial: Oral Ixazomib, Lenalidomide, and Dexamethasone (IRd) Vs Placebo-Rd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM). 2020. Available at: https://ash.confex.com/ash/2020/webprogram/Paper137007.html. Accessed on: 04 January 2021.
  • 26. Kazandjian D, Hill E, Morrison C, et al. Treatment of high risk (HR) smoldering multiple myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (krd) followed by Lenalidomide Maintenance (-R): A phase 2 clinical and correlative study. 2020. Available at: https://ash.confex.com/ash/2020/webprogram/Paper136148.html. Accessed on: 04 January 2021.
  • 27. Chen EC, Garcia JS. Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia? Hematology Am Soc Hematol Educ Program. 2020;2020(1):41–50.
  • 28. Alison R. Walker. How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2020;2020(1):51–56.
  • 29. Halpern AB, Walter RB. Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings. Hematology Am Soc Hematol Educ Program. 2020;2020(1):129–134.
  • 30. Villafuerte-Gutierrez P, Villalon L, Losa JE, et al. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: A critical review and update [published correction appears in Adv Hematol. 2019 Jul 16; 2019:4120631]. Adv Hematol. 2014;2014:986938
  • 31. Chua CC, Roberts AW, Reynolds J, et al. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined with Modified Intensive Chemotherapy. J Clin Oncol. 2020;38(30):3506–3517.
  • 32. Wei AH, Döhner H, Pocock C, et al. The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission. Blood. 2019;134 (Suppl 2):LBA–3.
  • 33. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–629.
  • 34. Kadia TM, Borthakur G, Pemmaraju N, et al. Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood. 2020;136 (Suppl 1):17–19.
  • 35. Esteve J, Schots R, Bernal Del Castillo T, et al. Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort. Blood. 2018;132 (Suppl 1):2736.
  • 36. De Botton S, Cluzeau T, Vigil CE, et al. SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia. Blood. 2020;136(Suppl 1):4–5.
  • 37. Stein EM, De Botton S, Cluzeau T, et al. Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia. 2020. Available at: https://ash.confex.com/ash/2020/webprogram/Paper134602.html. Accessed on: 04 January 2021.
  • 38. Pratz KW, Panayiotidis P, Recher C, et al. Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine. Blood. 2020;136(Suppl 1):33–35
  • 39. Malas MB, Naazie IN, Elsayed N, et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicines. 2020;29:100639.
  • 40. Kreuziger LB, Lee A, Garcia D, et al. American Society of Hematology. COVID-19 and VTE/Anticoagulation: Frequently Asked Questions. 2020. Available at: https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation. Accessed on: 04 January 2021.
  • 41. Canoglu K, Saylan B. Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection. Ann Saudi Med. 2020;40(6):462–468.